Xperimentations.ca Bibliographie sur l`ecstacy

Transcription

Bibliographie sur l’ecstasy, Xperimentations.ca
Bibliographie sur l’ecstasy
Aliciati, A., B. Scaramelli, A. Fusi, E. Butteri, M.L. Cattaneo et C. Mellado. Three cases of
delirium after “ecstasy” ingestion, Journal of Psychoactive Drugs, vol. 31, 1999, p.
167–170.
Allen, R., U.D. McCann et G.A. Ricaurte. Sleep in abstinent users of MDMA, Sleep, vol. 16,
1993, p. 560–564.
Anderson, J. Ecstasy, other designer drugs and the rave phenomenon, Ottawa, Division de la
Stratégie canadienne antidrogue, 2000.
Andreu, V., A. Mass, M. Bruguera, J.M. Salmeron, V. Moreno, S. Nogué et coll. Ecstasy: A
common cause of severe acute hepatoxicity, Journal of Hepatology, vol. 29, 1998, p.
394–397.
Baggott, M., B. Heifets, R.T. Jones, J. Mendelson, E. Sferios et B.S. Zehander. Chemical
analysis of ecstasy pills, Journal of the American Medical Association, vol. 284,
1997, p. 2190.
Barnes, D.M. New data intensify the agony over ecstasy, Science, vol. 239, 1988, p. 864–
866.
Beck, J. et M. Rosenbaum. Pursuit of ecstasy: The MDMA experience, Albany (NY), State
University of New York Press, 1994.
Behan, W.M., M. Madigan, B.J. Clark, J. Goldberg et D.R. McLellan. Muscle changes in
neuroleptic malignant syndrome, Journal of Clinical Pathology, vol. 53, 2000, p.
223–227.
Benazzi, F. et M. Mazzoli. Psychiatric illness associated with “ecstasy”, The Lancet, vol.
338, 1991, p. 1520.
Bolla, K.I., U.D. McCann et G.A. Ricaurte. Memory impairment in abstinent MDMA
(“ecstasy”) users: A controlled study, Neurobiology, vol. 51, 1998, p. 1532–1537.
Boot, B., I.S. McGregor et W. Hall. MDMA (ecstasy) neurotoxicity: Assessing and
communicating the risks, The Lancet, vol. 355, 2000, p. 1818–1821.
Bost, R.O. 3, 4-methylenedioxymethamphetamine (MDMA) and other substitute
amphetamines, Journal of Forensic Science, vol. 33, 1988, p. 576–587.
© Centre canadien de lutte contre l’alcoolisme et les toxicomanies | Novembre 2011
Page 2 de 15
Brown, E.R.S., D.R. Jarvie et D. Simpson. Use of drugs at ‘rave’, Scottish Medical Journal,
vol. 40, 1995, p. 168–171.
Cadet, J.L. et N. Thiriet. Acute transcriptional effects of MDMA on the rat cortex: Evidence
from cDNA analysis. Affiche présentée à MDMA/Ecstasy Research: Advances,
Challenges and Future Directions, Bethesda (MD), 2001. Cité par National Institute
on Drug Abuse. Ecstasy: What we know and don't know about MDMA: A scientific
review, 2001. Consulté sur le
http://archives.drugabuse.gov/meetings/MDMA/MDMAExSummary.html.
Campbell, G.A. et M.H. Rosner. The agony of ecstasy: MDMA (3,4methylenedioxymethamphetamine) and the kidney, Clinical Journal of the American
Society of Nephrology, vol. 3, 2008, p. 1852–1860.
Chadwick, I.S., P.D. Curry, A. Linsley, A.J. Freemont et B. Doran. Ecstasy, 3, 4methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy
and hyperthermia, Journal of the Royal Society of Medicine, vol. 84, 1991, p. 371.
Chang, L. Neuroimaging studies in chronic effects of recreational MDMA use. Affiche
présentée à MDMA/Ecstasy Research: Advances, Challenges and Future Directions,
Bethesda (MD), 2001. Cité par National Institute on Drug Abuse. Ecstasy: What we
know and don't know about MDMA: A scientific review, 2001. Consulté sur le
Chang, L., C.S. Grob, T. Ernst, L. Itti, F.S. Mishkin, R. Jose-Melchor et R.E. Poland. Effect
of ecstasy [3, 4 methylenedioxymethamphetamine (MDMA)] on cerebral blood flow:
A co-registered SPECT and MRI study, Psychiatry Research, vol. 98, 2000, p. 15–28.
Cohen, R.S. Adverse symptamology and suicide associated with the use of
methylenedioxymethamphetamine (MDMA: ‘ecstasy’), Biological Psychiatry, vol.
39, 1996, p. 816–818.
Cohen, R.S. Subjective reports on the effects of the MDMA (‘ecstasy’) experience in
humans, Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 19,
1995, p. 1137–1145.
Cooper, M.L. Alcohol use and risky sexual behavior among college students and youth:
Evaluating the evidence, Journal of Studies on Alcohol, vol. 14, 2002, p. 101–117.
Cottler, L.B., S.B. Womack, W.M. Compton et A. Ben-Abdallah. Ecstasy abuse and
dependence among adolescents and young adults: Applicability and reliability of
DSM-IV criteria, Human Psychopharmacology, vol. 16, 2001, p. 599–606.
Cowen, P.J. Serotonin receptor subtypes: Implications for psychopharmacology, British
Medical Journal, vol. 159, 1991, p. 7–14.
Page 3 de 15
Creighton, F.J., D.L. Black et C.E. Hyde. “Ecstasy” psychosis and flashbacks, British
Journal of Psychiatry, vol. 159, 1991, p. 713–715.
Curran, H.V. et R.A. Travill. Mood and cognitive effects of 3, 4methylenedioxymethampethamine (MDMA, ‘ecstasy’): Weekend ‘high’ followed by
mid-week ‘low’, Addiction, vol. 92, 1997, p. 821–831.
Darvesh, A.S., M. Shankaran et G.A. Gudelsky. MDMA produces glycogenolysis and
increases the extracelluluar concentration of glucose in the rat brain. Affiche
présentée à MDMA/Ecstasy Research: Advances, Challenges and Future Directions,
Bethesda (MD), 2001. Cité par National Institute on Drug Abuse. Ecstasy: What we
know and don't know about MDMA: A scientific review, 2001. Consulté sur le
de Win, M.M., G. Jager, J. Booij, L. Reneman, T. Schilt, C. Lavini, S.D. Olabarriaga, G.J.
den Heeten et W. van den Brink. Sustained effects of ecstasy on the human brain: A
prospective neuroimaging study in novel users, Brain, vol. 131, 2008, p. 2936–2945.
de la Torre, R., M. Farre et J. Ortuno. Non-linear pharmacokinetics of MDMA (‘ecstasy’) in
humans, British Journal of Clinical Pharmacology, vol. 49, 2000, p. 104–109.
Dafters, R.I., F. Duffy, P.J. O’Donnell et C. Bouquet. Level of use of 3, 4methylenedioxymethamphetamine (MDMA or ecstasy) in human correlated with
EEG power and coherence, Psychopharmacology, vol. 148, 1999, p. 322–324.
Drafters, R.I. et E. Lynche. Persistent lost of thermoregulation in the rate induced by 3, 4
methylenedioxymethamphetamine (MDMA or ‘ecstasy’) but not by fenfluramine,
Psychopharmacology, vol. 138, 2008, p. 207–212.
Dykhuizen, R.S., P.W. Brunt, P. Atkinson, J.G. Simpson et C.C. Smith. Ecstasy-induced
hepatitis mimicking viral hepatitis, Gut, vol. 36, 1995, p. 939–941.
Doblin, R.A. Clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress
disorder (PTSD): Partnering with the FDA, Journal of Psychoactive Drugs, vol. 4,
2002, p. 185–194.
Dowling, G.P., E.T. McDonough et R.O. Bost. “Eve” and “ecstasy”: A report of five deaths
associated with the use of MDEA and MDMA, Journal of the American Medical
Association, vol. 257, 1987, p. 1615–1617.
Duff, C. The pleasure in context, International Journal of Drug Policy, vol. 19, 2008, p.
384–392.
Ellis, A.J., J.A. Wendon, B. Portmann et R. Williams. Acute liver damage and
ecstasy ingestion, Gut, vol. 38, 1996, p. 454–458.
Page 4 de 15
Fahal, I.F., D.F. Sallomi, M. Yaqoob et G.M. Bell. Acute renal failure after ecstasy, British
Medical Journal, vol. 305, 1996, p. 29.
Fantegrossi, W., G. Winger, J. Woods, T. Ullrich, K. Rice, K. Kusxpit, P. Sherman et M.
Kilbourn. MDMA and its stereoisomers as reinforcers in rhesus monkeys:
Serotonergic involvement. Affiche présentée à MDMA/Ecstasy Research: Advances,
review, 2001. Consulté sur
lehttp://archives.drugabuse.gov/meetings/MDMA/MDMAExSummary.html.
Ferrie, R. et R.C. Loveland. Bilateral gluteal compartment syndrome after ‘ecstasy’
hyperpyrexia, Journal of the Royal Society of Medicine, vol. 93, 2000, p. 260.
Fidler, H., A. Dhillion, D. Hertner et A. Burroughs. Chronic ecstasy (3, 4methylenedioxymethampethamine) abuse: A recurrent and unpredictable cause of
severe acute hepatitis, Journal of Hepatology, vol. 25, 1996, p. 563–566.
Fleckenstein, A.E., E.L. Riddle, J.P. Hanson, V. Sandoval, J.M. Brown, J.W. Gibb et G.R.
Hanson. Methylenedioxymethamphatemine decreases plasmalemmal and vesicular
dopamine transport. Affiche présentée à MDMA/Ecstasy Research: Advances,
of Drug Abuse. Ecstasy: What we know and don't know about MDMA: A scientific
Frederick, D.L. et M.G. Paule. Effects of MDMA on complex brain functions in laboratory
animals, Neuroscience and Behavioral Review, vol. 27, 1997, p. 67–78.
Gamma, A., A. Buck, T. Berthold, D. Hell et F.X. Vollenweider. 3, 4methylenedioxymethampethamine (MDMA) modulates cortical and limbic brain
activity as measure by [H(2)(15)0]-PET in healthy humans,
Neuropsychopharmacology, vol. 23, 2000, p. 388–395.
Gay Men, Drug Use and HIV Workshop. Deconstructing Tina: A compendium guide to
crystal meth among gay and bisexual men, 2005. Consulté sur le
http://www.metrokc.gov/health/apu/harmred/deconstructing-tina.pdf.
Gerra, G., A. Zaimovic, M. Ferri, U. Zambelli, M. Timpano, E. Neri et coll. Long-lasting
effects of (+/-) 3, 4-methylenedioxymethamphetamine on serotonin system function
in humans, Biological Psychiatry, vol. 47, 2000, p. 127–136.
Gerra, G., A. Zaimovic, G. Guicastro, D. Maestri, C. Monica, R. Sartori et coll. Serotonergic
function after (+/-) 3, 4-methylenedioxymethamphetamine (‘ecstasy’) in humans,
International Clinical Psychopharmacology, vol. 13, 1998, p. 1–9.
Page 5 de 15
Glenhill, J.A., D.F. Moore, D. Bell et J.A. Henry. Subarachnoidal haemorrhage associated
with MDMA abuse, Journal of Neurology, Neurosurgery and Psychiatry, vol. 56,
1993, p. 1036–1037.
Golding, J.F., D.H. Groome, N. Rycroft et Z. Denton. Cognitive performance in light current
users and ex-users of ecstasy (MDMA) and controls, American Journal of Drug and
Alcohol Abuse, vol. 33, 2007, p. 301–307.
Gouzoulis-Mayfrank, E., J. Daumann, F. Tuchtenhagen, S. Peltz, S. Becker, H.J. Kunert, B.
Fimm et H. Sass. Impaired cognitive performance in drug free users of recreational
ecstasy (MDMA), Journal of Neurology, Neuroscience and Psychiatry, vol. 68, 2000,
p. 719–725.
Gouzoulis-Mayfrank, E., B. Thelen et E. Habermeyer. Psychopathological, neuroendocrine
and autonomic effects of 3, 4-methylenedioxyethylamphetamine (MDMA),
psilocybin and d-methamphetamine in healthy volunteers, Psychopharmacology, vol.
142, 1999, p. 41–50.
Gowing, L., S.M. Henry-Edwards, R.J. Irvine et R.L. Ali. The health effects of ecstasy: A
literature review, Drug and Alcohol Review, vol. 21, 2002, p. 53–63.
Green, A.R., A.J. Cross et G.M. Goodwin. Review of the pharmacology and clinical
pharmacology of 3,4-methylenedioxymethampethamine (MDMA or ecstasy),
Greer, G. et R. Tobert. Subjective reports of the effects of MDMA in a clinical setting,
Journal of Psychoactive Drugs, vol. 18, 1986, p. 319–327.
Grinspoon, L. et J.B. Bakalar. Can drugs be used to enhance the psychotherapeutic process?,
American Journal of Psychiatry, vol. 40, 1986, p. 393–404.
Hanson, G.R. Overview of MDMA-induced persistent neurotoxicity: Preclinical perspective.
Affiche présentée à MDMA/Ecstasy Research: Advances, Challenges and Future
Directions, Bethesda (MD), 2001. Cité par National Institute on Drug Abuse.
Ecstasy: What we know and don't know about MDMA: A scientific review, 2001.
Consulté sur le
Hatzidimitriou, G., U.D. McCann et G.A. Ricaurte. Altered serotonin innervation patterns in
the forebrain of monkeys treated with (+/-) 3, 4-methylenedioxymethamphetamine
seven years previously: Factors influencing abnormal recovery, Journal of
Neuroscience, vol. 19, 1999, p. 5096–5107.
Page 6 de 15
Hegadoren, K.M., G.B. Baker et M. Bourin. 3, 4-methylenedioxy analogues of amphetamine:
Defining the risk to humans, Neuroscience and Biobehavioral Reviews, vol. 23, 1999,
p. 539–553.
Henry, J.A., K.J. Jeffreys et S. Dawling. Toxicity and deaths from 3,4
methylenedioxymethamphetamine (ecstasy), The Lancet, vol. 340, 1992, p. 384–387.
Holmes, S.B., A.K. Banerjee et W.D. Alexander. Hyponatraemia and seizures after ecstasy
use, Postgraduate Medical Journal, vol. 75, 1999, p. 32–33.
Holden, R. et M.A. Jackson. Near-fatal hypnatraemia coma due to vaso-pressin oversecretion after “ecstasy” (3,4-MDMA), The Lancet, vol. 347, 1996, p. 1052.
Hughes, J.C., M. McCabe et R.J. Evans. Intracranial haemorrhage associated with ingestion
of ‘ecstasy’, Archives of Emergency Medicine, vol. 10, 1993, p. 372–374.
Hunt, P. et K. Evans. 'The great unmentionable': Exploring the pleasures and benefits of
ecstasy from the perspectives of drug users, Drugs: Education, Prevention and
Policy, vol. 15, 2008, p. 329–349.
Huxster, J.K., A. Pirona et M.J. Morgan. The sub-acute effects of recreational ecstasy
(MDMA) use: A controlled study in humans, Journal of Psychopharmacology, vol.
20, 2006, p. 281–290.
Irvine, R. ‘Ecstasy’ deaths: More than just MDMA: An Australian perspective. Présenté à
MDMA/Ecstasy Research: Advances, Challenges and Future Directions, Bethesda
(MD), 2001. Cité par National Institute on Drug Abuse. Ecstasy: What we know and
don't know about MDMA: A scientific review, 2001. Consulté sur le
James, J.S. “Poppers”, some other drugs, may increase HIV infection risk, 2004. Consulté
sur le http://www.thebody.com/atn/398/poppers.html.
Jones, A.L. et K.H. Simpson. Mechanisms and management of hepatoxicity in ecstasy
(MDMA) and amphetamine intoxications, Alimentary Pharmacology and
Therapeutics, vol. 13, 1999, p. 129–133.
Johnson, E.A., S. Benkovic, A.R. Little, K. Sriram, J.P. O’Callaghan et D.B. Miller.
Interactions of acute and chronic stress with d-MDMA-induced dopaminergic
neurotoxicity in the mouse. Affiche présentée à MDMA/Ecstasy Research: Advances,
Page 7 de 15
Kalant, H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs,
Journal de l'Association médicale canadienne, vol. 165, 2001, p. 917–928.
Kelly, P.A. Impaired cognitive performance in drug free users of creational ecstasy
(MDMA), Journal of Neurology and Neurosurgery Psychiatry, vol. 62, 2000, p. 418–
419.
Kessel, B. Hyponatraemia after ingestion of ecstasy, British Medical Journal, vol. 308, 1993,
p. 414.
Khakoo, S.I., C.J. Coles, J.S. Armstrong et R.E. Barry. Hepatoxicity and accelerated fibrosis
following 3, 4-methylenedioxymethamphetamine (“ecstasy”) usage, Journal of
Clinical Gastroenterology, vol. 20, 1995, p. 244–247.
Klitzman, R.L., J.D. Greenberg, L.M. Pollacks et C. Dolezal. MDMA (‘ecstasy’) use, and its
association with high risk behaviors, mental health, and other factors among
gay/bisexual men in New York City, Drug and Alcohol Dependence, vol. 66, 2002, p.
115–125
Klitzman, R.L., H.G. Pope et J.I. Hudson. MDMA (“ecstasy”) abuse and high risk sexual
behaviours among 169 gay and bisexual men, American Journal of Psychiatry, vol.
157, 2000, p. 1162–1164.
King, L.A. Was it MDMA?, Neuropsychobiology, vol. 42, 2000, p. 45–46.
Kish, S.J., Y. Furukawa, L. Angl, S.P. Vorce et K.S. Kalasinsky. Striatal serotonin is
depleted in the brain of a human MDMA (ecstasy) user, Neurology, vol. 55, 2000, p.
294–296.
Lester, S.J., M. Baggott, S. Welm, N.B. Schiller, R.T. Jones, E. Foster et J. Mendelson.
Cardiovascular effects of 3, 4-methylenedioxymethampethamine: A double-blind,
placebo-controlled trial, Annals of Internal Medicine, vol. 133, 2000, p. 969–973.
Levy, K.B., K.E. O’Grady, E.D. Wish et A.M. Arria. An in-depth qualitative examination of
the ecstasy experience: Results of a focus group with ecstasy-using college student,
Substance Use and Misuse, vol. 40, 2005, p. 1427–1441.
Liechti, M.E., A. Gamma et F.X. Vollenweider. Gender differences in the subjective affects
of MDMA, Psychopharmacology, vol. 154, 2001, p. 161–168.
Liechti, M.E., M.R. Saur, A. Gamma, D. Hell et F.X. Vollenweider. Psychological and
physiological effects of MDMA (‘ecstasy’) after pretreatment with the 5-HT2
antagonist Ketanserin in healthy humans, Neuropsychopharmacology, vol. 23, 2001,
p. 396–404.
Page 8 de 15
Liu, J., B. Jones, C. Grobe, C. Balram et C. Poulin. New Brunswick Student Drug Use Survey
2002: Highlights report, Fredericton, ministère de la Santé et du Mieux-être,
Nouveau-Brunswick, 2002.
Marston, H.M., M.E. Reid, J.A. Lawrence, H.J. Olverman et S.P. Butcher. Behavioral
analysis of the acute and chronic effects of MDMA treatment in the rat,
Mattison, A.M., M.W. Ross, T. Wolfson et D. Franklin. Circuit party attendance, club drug
use, and unsafe sex in gay men, Journal of Substance Abuse, vol. 13, 2001, p. 119–
126.
Maxwell, D.I., M.I. Polkey et J.A. Henry. Hypnatraemia and catatonic stupor after taking
ecstasy, British Medical Journal, vol. 307, 1993, p. 1339.
McCann, U.D. Induced brain serotonin neurotoxicity: Clinical studies. Affiche présentée à
don't know about MDMA: A scientific review, 2001.
McCann, U.D., V. Eligulashvilli, M. Mertl, D.L. Murphy et G.A. Ricaurte. Altered
neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3, 4methylenedioxymethamphetamine (MDMA) users, Psychopharmacology, vol. 147,
1999, p. 56–65.
McCann, U.D., V. Eligulashvilli et G.A. Ricaurte. 3, 4-methylenedioxymethampethamine
(‘ecstasy’)-induced serotonin neurotoxicity: Clinical studies, Neuropsychobiology,
vol. 42, 2000, p. 11–16.
McCann, U.D., M. Mertl, V. Eligulashvilli et G.A. Ricaurte. Cognitive performance in (+-)
3, 4-methylenedioxymethampethamine (MDMA, “ecstasy”) users: A controlled
study, Psychopharmacology, vol. 143, 1999, p. 417–425.
McCann, U.D., A. Ridenour, Y. Shaham et G.A. Ricaurte. Serotonin neurotoxicity after (+/-)
3, 4-methylenedioxymethamphetamine (MDMA; “ecstasy”): A controlled study in
humans, Neuropsychopharmacology, vol. 10, 1994, p. 129–138.
McCann, U.D., Z. Szabo, U. Scheffell, R.F. Dannals et G.A. Ricaurte. Positron emission
tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin
neurons in human beings, The Lancet, vol. 352, 1998, p. 1433–1437.
McElrath, K. MDMA and sexual behavior: Ecstasy users’ perceptions about sexuality and
sexual risk, Substance Use and Misuse, vol. 40, 2005, p. 1461–1477.
Page 9 de 15
McGuire, P.K. et T. Fahy. Chronic paranoid psychosis after misuse of MDMA (ecstasy),
British Medical Journal, vol. 203, 1991, p. 697.
McKirnan, D.J., P.A. Vanable, D.G. Ostrow et B. Hope. Expectancies of sexual “escape” and
sexual risk among drug and alcohol-involved gay and bisexual men, Journal of
Substance Abuse, vol. 13, 2001, p. 137–154.
Measham, F., H. Parker et J. Aldridge. The teenage transition: From adolescent recreational
drug use to the young adult dance culture in Britain in the mid 1990’s, Journal of
Drug Issues, vol. I, 1998, p. 9–32.
Mendolson, J. The pharmacology of ecstasy. Affiche présentée à MDMA/Ecstasy Research:
Advances, Challenges and Future Directions, Bethesda (MD), 2001. Cité par
National Institute on Drug Abuse. Ecstasy: What we know and don't know about
MDMA: A scientific review, 2001. Consulté sur le
Milosevic, A., N. Agrawal, P. Redfearn et L. Mair. The occurrence of toothwear in users of
ecstasy (3, 4-methylenedioxymethamphetamine), Community Dental and Oral
Epidemiology, vol. 27, 1999, p. 283–287.
Montgomery, C. et J.E. Fisk. Ecstasy-related deficits in the updating component of executive
processes, Human Psychopharmacology, vol. 23, 2008, p. 495–511.
Morgan, M.J. Recreation use of “ecstasy” (MDMA) is associated with elevated impulsivity,
Morgan, M.J. Memory deficits associated with recreational use of “ecstasy” (MDMA),
Morland, J. Toxicity of drug abuse: Amphetamine designer drugs (ecstasy): Mental effects
and consequences of a single dose use, Toxicology Letters, vol. 112–113, 2000, p.
147–152.
Newcombe, R.A. A researcher reports from the rave, Drug Link, vol. 7, 1992, p. 14.
National Institute on Drug Abuse. Ecstasy: What we know and don't know about MDMA: A
scientific review, 2001. Consulté sur le
Obrocki, J., R. Buchert, O. Vaterlein, R. Thomasius, W. Beyer et T. Schiemann. Ecstasy:
Long term effects on human central nervous system revealed by positron emission
tomography, British Journal of Psychiatry, vol. 175, 1999, p. 186–188.
Page 10 de 15
Oranje, W.A., P. von Pol, A. van der Wurff, R.N.M. Zeijen, R.W. Stockbrugge et J.W.
Arends. XTC-induced hepatitis, Netherlands Journal of Medicine, vol. 44, 1994, p.
56–59.
Ostrow, D. The role of drugs in the sexual lives of men who have sex with men: Continuing
barriers to researching this question, AIDS and Behavior, vol. 4, 2000, p. 205–219.
Pallanti, S. et D. Mazzi. MDMA (ecstasy) precipitation of panic disorder, Biological
Psychiatry, vol. 32, 1992, p. 91–95.
Parrott, A.C. Human psychopharmacology of ecstasy (MDMA): A review of 15 years of
empirical research, Human Psychopharmacology, vol. 16, 2001, p. 557–577.
Parrot, A.C. et J. Laskey. Ecstasy (MDMA) effects upon mood and cognition; Before, during
and after a Saturday night dance, Psychopharmacology, vol. 139, 1998, p. 261–268.
Parrott, A.C., E. Sisk et J.J. Turner. Psychobiological problems in heavy ‘ecstasy’ (MDMA)
polydrug users, Drug and Alcohol Dependence, vol. 60, 2000, p. 105–110.
Peroutka, S.J., H. Newman et H. Harris. Subjective effects of 3,4,
methylenedioxymethamphetamine in recreational users, Neuropharmacology, vol. 1,
1988, p. 272– 277.
Poulin, C. et B. Wilbur. Nova Scotia Student Drug Use Survey 2002: Technical
report, Halifax, Services de dépendance du ministère de la Santé de la NouvelleÉcosse et Université Dalhousie, 2002.
Purcell, D.W., J.T. Parsons, P.N. Halkitis, Y. Mizuno et W.J. Woods. Substance use and
sexual transmission risk behavior of HIV-positive men who have sex with men,
Journal of Substance Abuse, vol. 13, 2001, p. 185–200.
Randall, T. Ecstasy-fueled: Rave parties become dances of death for English youths, Journal
of the American Medical Association, vol. 268, 1997, p. 1505–1506.
Redfearn, P.J., N. Agrawal et L.H. Mair. An association between the regular use of 3,4,
methylenedioxymethamphetamine (“ecstasy”) and excessive wear of teeth, Addiction,
vol. 93, 1998, p. 745–748.
Reneman, L., J. Booij, C.B.L. Majoie, W. van den Brink et G.J. den Heeten. Investigating the
potential neurotoxicity of ecstasy (MDMA): An imaging approach, Human
Psychopharmacology: Clinical & Experimental, vol. 16, 2001, p. 579–588.
Reneman, L., J. Booij, B. Schmand, W. van den Brink et B. Gunning. Memory disturbances
in “ecstasy” users are correlated with an altered brain serotonin neurotransmission,
Page 11 de 15
Ricaurte, G.A. MDMA-induced brain serotonin neurotoxicity: Preclinical studies. Présenté à
don't know about MDMA: A scientific review, 2001. Consulté sur le
Ricaurte, G.A, G. Bryan, L. Strauss, L. Seiden et C. Schuster. Hallucinogenic amphetamine
selectivity destroys brain serotonin nerve terminals, Science, vol. 229, 1985, p. 986–
988.
Ricaurte, G.A., U.D. McCann, Z. Szabo et U. Scheffel. Toxicodynamics and long term
toxicity of the recreational drug, 3, 4-methylenedioxymethampethamine (MDMA,
‘ecstasy’), Toxicology Letters, vol. 112, 2000, p. 143–146.
Ricaurte, G.A., J. Yuan et U.D. McCann. 3, 4-methylenedioxymethamphetamine (‘ecstasy’)induced serotonin neurotoxicity: Studies in animals, Neuropsychobiology¸ vol. 42,
2000, p. 5–10.
Rudnick, G. et S.C. Wall. The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced
serotonin release, Proceedings of the National Academy of Sciences, vol. 89, 1992, p.
1817–1821.
Sherlock, K., K. Wolff, A.W. Hay et M. Connor. Analysis of illicit ecstasy tablets, Journal of
Accident and Emergency Medicine, vol. 16, 1999, p. 194–197.
Schifano, F. Potential human neurotoxicity of MDMA (‘ecstasy’): Subjective self-reports,
evidence from an Italian drug addiction centre and clinical case studies,
Neuropsychobiology, vol. 42, 2000, p. 25–33.
Schifano, F., L. Di Furia, G. Forza, N. Minicuci et R. Bricolo. MDMA (‘ecstasy’)
consumption in the context of polydrug abuse: A report of 150 patients, Drug and
Alcohol Dependence, vol. 52, 1998, p. 85–90.
Schmidt, C.J. et J.H. Kehne. Neurotoxicity of MDMA: Neurochemical effects, Annals of the
New York Academy of Sciences, vol. 600, 1990, p. 665–681.
Schierenbeck, T., D. Riemann, M. Berger et M. Hornyak. Effect of illicit recreational drugs
upon sleep: Cocaine, ecstasy and marijuana, Sleep Medicine Reviews, vol. 12, 2008,
p. 381–389.
Schwartz, R. et N.S. Miller. MDMA (ecstasy) and the rave: A review, Pediatrics, vol. 100,
1997, p. 705–708.
Page 12 de 15
Screaton, G.R., M. Singer, H.S. Cairns, A. Trasher, M. Sarner et S.L. Cohen. Hyperpyrexia
and rhabdomyolysis after MDMA (“ecstasy”) abuse, The Lancet, vol. 339, 1992, p.
677–678.
Shulgin, A.T. The background and chemistry of MDMA, Journal of Psychoactive Drugs,
vol. 18, 1986, p. 291–304.
Siegel, R.K. MDMA: Nonmedical use and intoxication, Journal of Psychoactive Drugs, vol.
18, 1986, p. 349–354.
Singer, L.T., T.J. Linares, S. Ntiri, R. Henry et S. Minnes. Psychosocial profiles of older
adolescent MDMA users, Drug and Alcohol Dependence, vol. 74, 2004, p. 245–252.
Simantov, R. et M. Tauber. The abused drug MDMA (ecstasy) induces programmed death of
human serotonergic cells, Federation of American Societies for Experimental Biology
Journal, vol. 11, 1997, p. 141–146.
Sola Lopis, S., M. Miguelez-Pan, J. Pena-Casanova, S. Poudevida, M. Farre, R. Pacifici, P.
Bohm, S. Abanades, A. Verdejo Garcia, K. Langohr, P. Zuccaro et R. de la Torre.
Cognitive performance in recreational ecstasy polydrug users: A two-year follow-up
study, Journal of Psychopharmacology, vol. 22, 2008, p. 498–510.
Spratt, J., B. Glawar et B. Mamoli. A pure amnesic syndrome after MDMA (‘ecstasy’)
ingestion, Journal of Neurology, Neuroscience and Psychiatry, vol. 62, 1997, p. 418.
State, R.C., C.S. Grob et R.E. Poland. Psychobiological effects of 3, 4methylenedioxymethampethamine in humans: A pilot study. Affiche présentée à
don't know about MDMA: A scientific review, 2001.
Sterk, C.E. A burning candle: Trends, challenges and future directions in MDMA research.
Affiche présentée à MDMA/Ecstasy Research: Advances, Challenges and Future
Directions, Bethesda (MD), 2001. Cité par National Institute on Drug Abuse.
Ecstasy: What we know and don't know about MDMA: A scientific review, 2001.
Consulté sur le
Stone, D.M., M. Johnson, G.R. Hanson et J.W. Gibb. Acute inactivation of tryptophan
hydroxylase by amphetamine analogs involves the oxidation of sulfhydrayl sites,
European Journal of Pharmacology, vol. 172, 1989, p. 294–296.
Suarez, R.V. et R. Riemersma. Ecstasy and sudden cardiac death, American Journal of
Forensic Medical Pathology, vol. 9, 1988, p. 339–341.
Page 13 de 15
Tancer, M.E. et C.E. Johanson. The subjective effects of MDMA and mCPP in moderate
MDMA users, Drug and Alcohol Dependence, vol. 65, 2001, p. 97–101.
Theall, K.P, K.W. Elifson et C.E. Sterk. Sex, touch, and HIV risk among ecstasy users, AIDS
and Behavior, vol. 10, 2006, p. 169–178.
Topp, L., W. Hall et J. Hando. Is there a dependence syndrome for ecstasy? (National Drug
and Alcohol Research Centre Technical Report No. 51), Sydney (Australie),
Université de la Nouvelle-Galles du Sud, 1997.
Topp, L., J. Hando et P. Dillon. Sexual behaviour of ecstasy users in Sydney, Australia,
Culture, Health and Sexuality, vol. 1, 1999, p. 147–159.
Twitchell, G.R., M.R. Davis, A.D. Kalechstein et T.F. Newton. Neurocognitive impairment
in MDMA users: A meta-analytic review. Affiche présentée à MDMA/Ecstasy
Research: Advances, Challenges and Future Directions, Bethesda (MD), 2001. Cité
par National Institute on Drug Abuse. Ecstasy: What we know and don't know about
MDMA: A scientific review, 2001. Consulté sur le
Vaiva, G., V. Boss, V. Bailly, P. Thomas, P. Lestavel et M. Goudemand. An ‘accidental’
acute psychosis with ecstasy use, Journal of Psychoactive Drugs, vol. 33, 2001, p.
95–96.
Verheyden, S.L., J.A. Henry et H.V. Curran. Acute, sub-acute and long-term subjective
consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users, Human
Verkes, R.J., H.J. Gijsman, M.S. Pieters, R.C. Schoemaker, S. de Visser, M. Kuijpers, E.J.
Pennings, D. de Bruin, G. van de Wijngaart, J.M. van Gerven et A.F. Cohen.
Cognitive performance and serotonergic function in users of ecstasy,
Vollenweider, F.X., A. Gamma, M. Liechti et T. Huber. Is a single dose of MDMA harmless,
Wareing, M., J.E. Fisk et P.N. Murphy. Working memory deficits in current and previous
users of MDMA (‘ecstasy’), British Journal of Psychology, vol. 91, 2000, p. 181–
188.
Weir, E. Raves: A review of the culture, the drugs and the prevention of harm, Journal de
l'Association médicale canadienne, vol. 162, 2000, p. 1843–1849.
Whitaker-Azmitia, P.M. et T.A. Aronson. ‘Ecstasy’ (MDMA)- induced panic, American
Journal of Psychiatry, vol. 146, 1989, p. 119.
Page 14 de 15
Williams, H., L. Dratcu, R. Taylor, M. Roberts et A. Oyefeso. “Saturday night fever”:
Ecstasy related problems in a London accident and emergency department, Journal of
Accidental and Emergency Medicine, vol. 15, 1998, p. 322–326.
Williams, H., D. Meagher et P. Galligan. MDMA (“ecstasy”): A case of possible druginduced psychosis, Irish Journal of Medical Science, vol. 162, 1993, p. 43–44.
White, B., L. Degenhardt, C. Breen, R. Bruno, J. Newman et P. Proudfoot. Risk and benefit
perceptions of party drug use, Addictive Behaviors, vol. 31, 2006, p. 137–142.
Wolff, K., A.W.M. Hay, K. Sherlock et M. Connor. Contents of “ecstasy”, The Lancet, vol.
346, 1995, p. 1100–1101.
Yamamoto, B.K. Neurochemical mediators and neurophysiological consequences of acute
MDMA exposure in rats. Affiche présentée à MDMA/Ecstasy Research: Advances,
Zemishlany, Z., D. Aizenberg et A. Weizman. Subjective effects of MDMA (‘ecstasy’) on
human sexual function, European Psychiatry, vol. 16, 2001, p. 127–130.
Centre canadien de lutte contre l’alcoolisme et les toxicomanies
75, rue Albert, bureau 500 | Ottawa (Ontario) K1P 5E7 | Canada
Tél. : 613-235-4048 | Téléc. : 613-235-8101 | [email protected]
Page 15 de 15

Xperimentations.ca Bibliographie sur l`ecstacy

Transcription

Documents pareils

Identification d`un nouveau comprimé d`ecstasy

Circulation de nouveaux comprimés d`ecstasy - Infor

Existe-t-il une interaction entre le citalopram et l`ecstasy?

Les drogues et leurs effets

Le probLème de La date d`expiration Vos spécialistes

Dictionnaire des drogues et des pratiques toxicomanes

Focus - Ecstasy - Addiction Suisse

Cocaïne - Amphétamines - MDMA - Ecstasy Ce qu`il faut savoir sur

system of narcotics identification

Les drogues les plus consommées chez les adolescents